Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.61 |
| ▸ | MAOA | P21397 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.55 |
| ▸ | PTGES | O14684 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30361330 | 1.00 | MAOB (0.61) | MAOBMAOAMAPTCYP2C9CYP2C19 | |
| SCHEMBL30591972 | 0.88 | PTGDR2 (0.67) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL6452235 | 0.88 | PTGDR2 (0.67) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL16898127 | 0.88 | FOLH1 (0.58) | L3MBTL1LRRK2PTGES | |
| SCHEMBL31053310 | 0.88 | SMN1; SMN2 (0.54) | MAOBMAOAMAPTCYP2C9CYP2C19 | |
| SCHEMBL30133911 | 0.86 | MAOB (0.63) | MAOBMAOALRRK2 | |
| SCHEMBL14891403 | 0.86 | FFAR4 (0.54) | LRRK2PTGES | |
| SCHEMBL28317383 | 0.86 | NPC1 (0.53) | MAOBMAOASMN1; SMN2LRRK2PTGES | |
| SCHEMBL19361431 | 0.85 | PTGES (0.52) | MAOBLRRK2PTGES | |
| SCHEMBL6191453 | 0.85 | MAOB (0.51) | MAOBMAOAMAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782995-B1 | SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-3694856-B1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-3694856-B1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-10966970-B2 | Fused tricyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-10966970-B2 | Fused tricyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| EP-3782995-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-02-24 | — | — | EP | disclosed |
| US-20200113879-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-04-16 | — | — | US | disclosed |
| WO-2019201291-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | 中国科学院上海药物研究所 | 2019-10-24 | — | — | WO | disclosed |
| WO-2019100735-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-05-31 | — | — | WO | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| EP-0555068-B1 | Oxime derivatives as 5-lipoxygenase inhibitors | ZENECA LTD (GB) | 1996-04-10 | — | — | EP | disclosed |
| US-5482966-A | LIPOXYGENASE ENZYME INHIBITORS AS ANTIINFLAMMATORY AGENTS | ZENECA LIMITED (GB) | 1996-01-09 | — | — | US | disclosed |
| US-5332757-A | Enzyme inhibitors | ZENECA LIMITED (GB) | 1994-07-26 | — | — | US | disclosed |
| EP-0555068-A1 | Oxime derivatives as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1993-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | MAOB 3407/4885MAOA 3767/4885MAPT 4835/4885 |
| US-10966970-B2 | Fused tricyclic compounds and uses thereof in medicine | SLC10A1, CYP11B2, CYP11B1 | MAOB 64/4885MAOA 240/4885MAPT 160/4885 |
| US-20200113879-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SLC10A1, CYP11B2, CYP11B1 | MAOB 64/4885MAOA 240/4885MAPT 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.